Search the Newsroom
Filter By
News Type
Showing 1 - 8 of 8 results
From Mystery Mass to Targeted Therapy: How Genomics Changed Care for Two Infants
Two new CHOP Cancer Center case reports show that picking the right genetic test matters – using the wrong assay can miss actionable alterations and change treatment options.
Children’s Hospital of Philadelphia Pediatric Cancer Researcher Receives Prestigious Grant for Advancing Rare Tumor Studies
Children’s Hospital of Philadelphia (CHOP) is excited to announce that Theodore W. Laetsch, MD, a pediatric oncologist and principal investigator in the Advanced Personalized Therapeutics and Precision Surgery Program, was awarded a $1 million multi-year grant from the National Cancer Institute (NCI).
Children’s Hospital of Philadelphia researchers find precision medicine treatment delivers strong results for infantile fibrosarcoma and other solid tumors
Researchers at Children’s Hospital of Philadelphia (CHOP) and the Children’s Oncology Group (COG) found that larotrectinib, an oral drug that stops cancer-cell growth, was highly effective in pediatric patients with newly diagnosed infantile fibrosarcoma (IFS) or other solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. The study, published today in the Journal of Clinical Oncology, is the first COG trial to test precision medicine in a front-line setting across all different types of solid tumors based on a genetic biomarker rather than histology. It is poised to redefine the approach to treatment for newly diagnosed fibrosarcoma and other solid tumors with the NTRK gene fusion, potentially reducing or eliminating the need for these patients to receive chemotherapy.
Children’s Hospital of Philadelphia Receives Multi-Million Dollar Gift from Holveck Family to Support Groundbreaking Osteosarcoma Research
Children’s Hospital of Philadelphia (CHOP) has received a $6.4 million gift from the family of Connor Boyle, a Central Bucks East High School graduate who died at age 18 from osteosarcoma. This three-year gift, named The Connor Initiative: Precision Therapeutics for Osteosarcoma & Rare Cancers, will support cutting-edge research in osteosarcoma and other rare cancers.
Case Study: Precision Medicine for Infantile Fibrosarcoma
Levy traveled from Brazil and participated in a clinical trial for an oral drug that targets an NTRK gene fusion that drives cancer-cell growth.
Integrating Precision Medicine into Standard of Care for Children with Thyroid Cancer
Read this case study about integrating precision medicine into the standard of care for children with thyroid cancer.
CHOP Brings Together Experts to Discuss Precision Medicine in Pediatric Cancer Care
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
Theodore Laetsch Joins Children’s Hospital of Philadelphia to Launch Very Rare Malignant Tumors Program
A national leader in pediatric oncology research and treatment, Dr. Laetsch will also lead CHOP’s Developmental Therapeutics Program.